# Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

> **NCT03715023** · PHASE2 · TERMINATED · sponsor: **Pulmocide Ltd** · enrollment: 5 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** PC786
- **DRUG:** Placebo
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT03715023
- **Lead sponsor:** Pulmocide Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-05
- **Primary completion:** 2019-02-19
- **Final completion:** 2019-05-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Practical issues that could not be resolved resulting in recruitment difficulties at sites.
- **Last updated:** 2019-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715023, "Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03715023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*